Advances in biology, diagnosis and treatment of DLBCL.

Ann Hematol · 2024 · PMC11358236 · PMID 39017945

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a phase III trial, consisting of 570 ABC-DLBCL patients, lenalidomide was added with a slightly different schedule from the previous study, although patients with high-risk diseases (IPI score 3 or more) showed a trend favoring R2-CHOP over placebo/RCHOP, the PFS did not improve [ 149 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.